Covalent Metal-Complex Platform Maps Proteome-Wide Cysteines, Nets a PRMT1 Inhibitor
- Introduces reactive metallo-scaffolds (r-mS), a new class of covalent metal complexes bearing a chloroacetamide electrophile designed to engage ligandable cysteines across the proteome.
- Chemoproteomic profiling of a focused r-mS series in HEK293T cell lysate mapped novel cysteine engagement proteome-wide.
- Metal identity, arene substituents, and overall scaffold topography together tune cysteine reactivity and targeting selectivity.
- Lead compound r-mS-2 engages a cysteine within the functionally relevant SAM-binding domain of the methyltransferase PRMT1, confirmed by intact-protein LC-MS.
- That engagement functionally inhibits PRMT1 activity, tying a covalent hit directly to modulation of a validated target.
- Positions the platform as a generalizable route to target discovery for rational, next-generation metallodrug design.
The SAM-pocket cysteine hit on PRMT1 is the part I trust most here — that's a genuinely druggable site, and confirming occupancy by intact-protein LC-MS rather than an activity readout alone is the right bar. Where I'd slow down is selectivity: tuning reactivity through metal identity and arene substituents is a real lever, but it's one more variable than iodoacetamide/chloroacetamide fragment libraries already juggle, and a lysate screen doesn't tell me the off-target cysteine load in cells. Chemically, this is genuinely unfamiliar ground for most of us — ligand exchange, redox lability, and batch-to-batch reproducibility are liabilities organic warheads simply don't have. Against established cysteine-directed chemoproteomic platforms, r-mS adds an interesting third tuning axis, not yet a clear win. Metallodrugs as a class still carry that same tractability tax relative to organic small molecules — worth watching, not yet worth reaching for.